Page 10 - Read Online

on glioma cells depends upon the expression of CARs a platform for further genetic modifications and
on their surface. The vector produced by the insertion combination treatments. Since the first clinical trials
of RGD peptide, named Ad-Δ24-RGD, can overcome have assured its safety, it is important for the future
this problem since it can directly bind to cell surface research to seek for enhancements in its genome and
integrins. [17] combining agents that could refine its effect.

Furthermore, a number of studies have focused on REFERENCES
augmenting the oncolytic potency of Ad-Δ24. Genetic
manipulations were used in order to produce vectors 1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic
expressing p53, [18] TRAIL and Arresten, [19] cytosine 2. engineering. Mol Ther 2007;15:651‑9.
Vacchelli E, Eggermont A, Sautès‑Fridman C, Galon J, Zitvogel L,
deaminase [20] and the tissue inhibitor of matrix Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer
metalloproteinase-3. [21] All these Ad-Δ24 derivatives therapy. Oncoimmunology 2013;2:e24612.
are claimed to be superior to the initial vector but their 3. Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver
efficacy awaits further confirmation. metastasis: relationship between tumor morphology and adenovirus
vector transduction. Mol Ther 2004;9:650‑7.
4. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus
COMBINATION TREATMENTS vectors to tumor cells does not enable efficient transduction of breast
cancer metastases. Cancer Res 2002;62:1063‑8.
Other studies have tried to improve the therapeutic 5. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E,
effect of Ad-Δ24 and its derivatives through combining Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM,
Oldfield EH. Therapy of malignant brain tumors by intratumoral
treatments with apoptotic and chemotherapeutic implantation of retroviral vector‑producing cells. Nat Med
agents, as well as radiation. Treatment to glioma with 1997;3:1354‑61.
Ad-Δ24 or its derivatives has been observed to enhance 6. Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and
when combined with TRAIL, [16] adenovirus expressing 7. their implications in gene delivery. Virus Res 2009;143:184‑94.
Cairns R, Papandreou I, Denko N. Overcoming physiologic
[22]
p53, temozolomide, radiation and topoisomerase barriers to cancer treatment by molecularly targeting the tumor
[23]
[24]
I inhibitor irinotecan. [25] Autophagic induced cell death microenvironment. Mol Cancer Res 2006;4:61‑70.
and induction of apoptosis are well-characterized 8. Fang J, Nakamura H, Maeda H. The EPR effect: unique features
results of Ad-Δ24 infection giving the erratum for of tumor blood vessels for drug delivery, factors involved, and
combination treatments. [26] limitations and augmentation of the effect. Adv Drug Deliv Rev
2011;63:136‑51.
9. Ottolino‑Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent
ANTITUMOR IMMUNE RESPONSE design: combination therapy with oncolytic viruses. Mol Ther
2010;18:251‑63.
10. Morrison J, Briggs SS, Green N, Fisher K, Subr V, Ulbrich K, Kehoe S,
Another important aspect of oncolytic virotherapy Seymour LW. Virotherapy of ovarian cancer with polymer‑cloaked
is the induction of augmented antitumor immune adenovirus retargeted to the epidermal growth factor receptor. Mol
response. [27,28] Ad-Δ24-RGD has been shown to Ther 2008;16:244‑51.
induce antiglioma immunity and to enhance the 11. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secretally:
presentation of tumor-associated antigens to immune immunostimulation by anticancer drugs. Nat Rev Drug Discov
2012;11:215‑33.
cells. [29] These findings provide the base for further 12. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R.
genetic manipulation of Ad-Δ24 in order to drive Hyaluronidase expression by an oncolytic adenovirus enhances
the production of immunostimulatory factors (like its intratumoral spread and suppresses tumor growth. Mol Ther
granulocyte-macrophage colony stimulating factor) that 2010;18:1275‑83.
can possibly mediate more robust therapeutic effects. [30] 13. Fueyo J, Gomez‑Manzano C, Alemany R, Lee PS, McDonnell TJ,
Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant
oncolytic adenovirus targeting the Rb pathway produces anti‑glioma
CLINICAL TRIALS effect in vivo. Oncogene 2000;19:2‑12.
14. Whyte P, Williamson NM, Harlow E. Cellular targets for
transformation by the adenovirus E1A proteins. Cell 1989;56:67‑75.
Ad-Δ24 and its derivatives have been tested in clinical 15. Kyritsis AP, Sioka C, Rao JS. Viruses, gene therapy and stem cells for
trials in patients with solid tumors, and more studies are the treatment of human glioma. Cancer Gene Ther 2009;16:741‑52.
in progress. The first results show that these agents are 16. Tsamis KI, Alexiou GA, Vartholomatos E, Kyritsis AP. Combination
safe, but their antitumor efficacy remains modest. [30,31] treatment for glioblastoma cells with tumor necrosis factor‑related
Ad-Δ24-RGd is also being tested in a clinical trial in apoptosis‑inducing ligand and oncolytic adenovirus delta‑24.
Cancer Invest 2013;31:630‑8.
patients with malignant gliomas and the results are 17. Fueyo J, Alemany R, Gomez‑Manzano C, Fuller GN, Khan A,
still pending. Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R,
Curiel DT, Yung WK, Lang FF. Preclinical characterization of the
CONCLUSION antiglioma activity of a tropism‑enhanced adenovirus targeted to
the retinoblastoma pathway. J Natl Cancer Inst 2003;95:652‑60.
18. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J,
Ad-Δ24 is a promising agent for glioblastoma treatment. Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van
The initial vector developed 14 years ago providing Beusechem VW. Oncolytic activity of p53‑expressing conditionally

2 Neuroimmunol Neuroinflammation | Volume 2 | Issue 1 | January 15, 2015